

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

DELAY IN DESPATCH OF CIRCULAR FOR MAJOR TRANSACTION

Reference is made to the announcement of the Company dated 30 September 2020 (the “**Announcement**”) in relation to the Company’s proposed acquisition of a controlling stake in Boya Bio-pharmaceutical Group Co., Ltd and the announcement of the Company dated 23 October 2020 (the “**Delay Announcement**”). Unless otherwise defined herein or the context requires, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement and the Delay Announcement.

As stated in the Delay Announcement, the Company has applied to the Stock Exchange for the Waiver from strict compliance with Rule 14.41(a) of the Listing Rules which requires the Circular to be despatched to the Shareholders on or before 23 October 2020, and the expected date of despatch of the Circular was on or before 15 December 2020. As further additional time is required to prepare and finalise, among other things, the financial information to be included in the Circular, subject to comments from the regulators, it is expected that the Circular will be despatched on or before 24 December 2020.

Further announcement(s) will be published by the Company in respect of its application for the Waiver or when there are any matters which may affect the abovementioned schedule.

Shareholders and potential investors should note that the transactions contemplated under the Transaction Documents are subject to the fulfilment of the conditions precedent stated in the Transaction Documents and may or may not proceed. Accordingly, Shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
China Resources Pharmaceutical Group Limited
WANG Chuncheng
Chairman

Shenzhen, 14 December 2020

As at the date of this announcement, the Board comprises Mr. WANG Chuncheng as chairman and non-executive Director, Mr. HAN Yuewei, Mr. LI Xiangming and Mdm. WENG Jingwen as executive Directors, Mr. YU Zhongliang, Mdm. GUO Wei, Mr. WANG Shouye and Mr. LYU Ruizhi as non-executive Directors and Mdm. SHING Mo Han Yvonne, Mr. KWOK Kin Fun, Mr. FU Tingmei and Mr. ZHANG Kejian as independent non-executive Directors.